FIELD: medicine.
SUBSTANCE: modification coefficient is calculated by formula: where M is a modification coefficient of each factor, Ai is one of factors under consideration, Amax and Amin are ranges of factors in healthy persons and hypertensive patients. For cholesterol (Mch) there are Amin=1.0, Amax=8.8 mmol/l; for triglycerides (Mtg) there are Amin=0.2, Amax=7.5 mmol/l, for beta-lipoproteins (Mlp) there are Amin=0.5, Amax=7.0 mmol/l, for atherogenicity coefficient (Mac) there are Amin=0.5, Amax=8.0, for adrenoreactivity level of red blood cell membranes (Marm) there are Amin=1.0, Amax=98 standard units, for variation pulsometry - mode amplitude (MAm) Amin=3.5, Amax=98%, stress-index (MSi) Amin=2.0, Amax=950 standard units, low-frequency subspectrum (MLF) Amin=5.0, Amax=90%, for visual-motor response measurements there are simple motor reaction time (Msmr) Amin=170, Amax=750 ms, complex motor reaction time for green light (Mcmr green) Amin=200, Amax=950 ms, complex visual-motor reaction time for red light (Mcmr red) Amin=200, Amax=950 ms, advance time (Mat) Amin=0.1, Amax=200 ms, delay time (Mdt) Amin=0.l, Amax=200 ms, for cardiovascular system measures there are systolic blood pressure (Msbp) Amin=85, Amax=200 mm Hg, diastolic blood pressure (Mdbp) Amin=50, Amax=120 mm Hg, stroke volume index (Msvi) Amin=1.3, Amax=6.0 l*min/m2, end-diastolic volume (Medv) Amin=62, Amax=220 ml, end-systolic volume (Mesv) Amin=15, Amax=120 ml, cardiac rate (Mcr) Amin=62, Amax=220 bpm. Then metabolic function index (MFI), regulatory system index (RSI), psychophysiological function index (PFI), cardiovascular system index (CSI) are to be calculated
. Provided MFI is less than 9 units, RSI is less than 10 units, PFI is less than 10 units, and CSI does not exceed 14 units, standard state is certified, while higher levels indicate that correction of the relevant systems is required.
EFFECT: extended range of aids used to assess health of operators.
12 tbl, 4 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD FOR DETECTION OF DEFATIGATION IN OPERATORS | 2011 |
|
RU2467683C1 |
METHOD FOR EVALUATING HEART ISCHEMIA DISEASE PATIENT TREATMENT EFFECTIVENESS BY APPLYING ESSENTIAL PHOSPHOLIPIDS | 1995 |
|
RU2121808C1 |
METHOD FOR DETERMINING INDIVIDUAL SENSITIVITY TO BETA-ADRENOCEPTOR BLOCKERS IN ARTERIAL HYPERTENSION CASES | 2003 |
|
RU2265846C2 |
METHOD OF PREDICTING RISK OF DEVELOPING VEGETO-VASCULAR DYSTONIA BY SYMPATHYCOTONIC TYPE IN TEENAGE BOYS | 2010 |
|
RU2439573C1 |
METHOD FOR ASSESSING RECOVERY OF FUNCTIONAL STATE OF QUALIFIED ATHLETES | 2023 |
|
RU2823684C1 |
METHOD FOR DETERMINING METABOLICALLY HEALTHY AND METABOLICALLY UNHEALTHY OBESITY IN YOUNG AND MIDDLE-AGED WOMEN | 2023 |
|
RU2822965C1 |
METHOD FOR ASSESSING FUNCTIONAL EFFECTIVENESS OF TEACHERS | 2022 |
|
RU2817036C2 |
METHOD FOR PREVENTING THE DEVELOPMENT OF ATHEROSCLEROSIS | 2005 |
|
RU2290907C1 |
METHOD FOR INTEGRATED ASSESSMENT OF FUNCTIONAL STATE OF STRESS STIMULATED BODY | 2013 |
|
RU2510621C1 |
METHOD FOR METABOLIC SYNDROME CORRECTION WITH USE OF MARE'S MILK AND HYPOBAROTHERAPY | 2012 |
|
RU2472514C1 |
Authors
Dates
2009-08-20—Published
2008-04-17—Filed